USE OF NUPR1 IN DIAGNOSIS AND TREATMENT OF BRAIN TUMOR

The present invention relates to use of nuclear protein 1 (NUPR1) in diagnosing and treating brain tumors and, more particularly, to a biomarker composition comprising NUPR1 for diagnosing brain tumors or for predicting prognosis and a composition comprising an NUPR1 inhibitor for preventing or trea...

Full description

Saved in:
Bibliographic Details
Main Authors KIM, Yo Na, OH, Mi Kyoung, PAEK, Sun Ha, HAN, Beom Ku, KIM, Hyun Il, SONG, Min Kyu
Format Patent
LanguageEnglish
French
Korean
Published 04.01.2018
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The present invention relates to use of nuclear protein 1 (NUPR1) in diagnosing and treating brain tumors and, more particularly, to a biomarker composition comprising NUPR1 for diagnosing brain tumors or for predicting prognosis and a composition comprising an NUPR1 inhibitor for preventing or treating brain tumors. The level of NUPR1, particularly NUPR1 isoform A, according to the present invention is significantly increased in patients with brain tumors and further remarkably in patients with malignant brain tumors of poor prognosis, compared to healthy normal persons, so that NUPR1 can be used as a biomarker for diagnosis of brain tumors or for prediction of prognosis. In addition, NUPR1, particularly NUPR1 isoform A according to the present invention can be used as a target for brain tumor treatment and also, in future, in screening a therapeutic agent for brain tumors as the inhibition thereof can suppress the growth, metastasis and invasion of brain tumors. La présente invention concerne l'utilisation d'une protéine nucléaire (1) (NUPR1) dans le diagnostic et le traitement des tumeurs au cerveau et, plus particulièrement, une composition de biomarqueur comprenant NUPR1 pour le diagnostic des tumeurs au cerveau ou pour prédire le prognostic et une composition comprenant un inhibiteur NUPR1 pour prévenir ou traiter les tumeurs au cerveau. Le niveau de NUPR1, particulièrement l'isoforme (A) de NUPR1, selon la présente invention, est significativement accru chez les patients présentant des tumeurs au cerveau et remarquablement en outre chez les patients présentant des tumeurs malignes au cerveau d'un prognostic médiocre, comparé aux personnes normales saines, de telle sorte que NUPR1 peut être utilisé comme biomarqueur pour le diagnostic des tumeurs au cerveau ou pour la prédiction d'un prognostic. De plus, NUPR1, particulièrement l'isoforme (A) de NUPR1, selon la présente invention, peut être utilisé comme cible de traitement de la tumeur au cerveau et également, dans le futur, dans le criblage d'un agent thérapeutique pour les tumeurs au cerveau dans la mesure où son inhibition peut supprimer la croissance, la métastase et l'invasion de tumeurs au cerveau. 본 발명은 뇌종양의 진단 및 치료에서의 NUPR1의 용도에 관한 것으로, 보다 구체적으로 본 발명은 NUPR1(Nuclear protein 1)을 포함하는 뇌종양 진단 또는 예후 예측용 바이오 마커 조성물 및 NUPR1 억제제를 포함하는 뇌종양 예방 또는 치료용 조성물에 관한 것이다. 본 발명에 따른 NUPR1, 특히 NUPR1 동형 A는 건강한 정상인에 비해 뇌종양 환자에서 유의하게 증가하며, 특히 예후가 나쁜 악성 뇌종양 환자에서 더욱 현저하게 증가하는바, 이를 뇌종양 진단 또는 예후 예측용 바이오 마커로 활용할 수 있다. 또한, 본 발명에 따른 NUPR1, 특히 NUPR1 동형 A의 억제를 통해 뇌종양의 성장, 전이 및 침입을 억제할 수 있는바, 이를 뇌종양 치료를 위한 타겟으로 활용할 수 있고, 향후 뇌종양 치료제의 스크리닝에도 이용할 수 있다.
AbstractList The present invention relates to use of nuclear protein 1 (NUPR1) in diagnosing and treating brain tumors and, more particularly, to a biomarker composition comprising NUPR1 for diagnosing brain tumors or for predicting prognosis and a composition comprising an NUPR1 inhibitor for preventing or treating brain tumors. The level of NUPR1, particularly NUPR1 isoform A, according to the present invention is significantly increased in patients with brain tumors and further remarkably in patients with malignant brain tumors of poor prognosis, compared to healthy normal persons, so that NUPR1 can be used as a biomarker for diagnosis of brain tumors or for prediction of prognosis. In addition, NUPR1, particularly NUPR1 isoform A according to the present invention can be used as a target for brain tumor treatment and also, in future, in screening a therapeutic agent for brain tumors as the inhibition thereof can suppress the growth, metastasis and invasion of brain tumors. La présente invention concerne l'utilisation d'une protéine nucléaire (1) (NUPR1) dans le diagnostic et le traitement des tumeurs au cerveau et, plus particulièrement, une composition de biomarqueur comprenant NUPR1 pour le diagnostic des tumeurs au cerveau ou pour prédire le prognostic et une composition comprenant un inhibiteur NUPR1 pour prévenir ou traiter les tumeurs au cerveau. Le niveau de NUPR1, particulièrement l'isoforme (A) de NUPR1, selon la présente invention, est significativement accru chez les patients présentant des tumeurs au cerveau et remarquablement en outre chez les patients présentant des tumeurs malignes au cerveau d'un prognostic médiocre, comparé aux personnes normales saines, de telle sorte que NUPR1 peut être utilisé comme biomarqueur pour le diagnostic des tumeurs au cerveau ou pour la prédiction d'un prognostic. De plus, NUPR1, particulièrement l'isoforme (A) de NUPR1, selon la présente invention, peut être utilisé comme cible de traitement de la tumeur au cerveau et également, dans le futur, dans le criblage d'un agent thérapeutique pour les tumeurs au cerveau dans la mesure où son inhibition peut supprimer la croissance, la métastase et l'invasion de tumeurs au cerveau. 본 발명은 뇌종양의 진단 및 치료에서의 NUPR1의 용도에 관한 것으로, 보다 구체적으로 본 발명은 NUPR1(Nuclear protein 1)을 포함하는 뇌종양 진단 또는 예후 예측용 바이오 마커 조성물 및 NUPR1 억제제를 포함하는 뇌종양 예방 또는 치료용 조성물에 관한 것이다. 본 발명에 따른 NUPR1, 특히 NUPR1 동형 A는 건강한 정상인에 비해 뇌종양 환자에서 유의하게 증가하며, 특히 예후가 나쁜 악성 뇌종양 환자에서 더욱 현저하게 증가하는바, 이를 뇌종양 진단 또는 예후 예측용 바이오 마커로 활용할 수 있다. 또한, 본 발명에 따른 NUPR1, 특히 NUPR1 동형 A의 억제를 통해 뇌종양의 성장, 전이 및 침입을 억제할 수 있는바, 이를 뇌종양 치료를 위한 타겟으로 활용할 수 있고, 향후 뇌종양 치료제의 스크리닝에도 이용할 수 있다.
Author KIM, Yo Na
HAN, Beom Ku
PAEK, Sun Ha
KIM, Hyun Il
OH, Mi Kyoung
SONG, Min Kyu
Author_xml – fullname: KIM, Yo Na
– fullname: OH, Mi Kyoung
– fullname: PAEK, Sun Ha
– fullname: HAN, Beom Ku
– fullname: KIM, Hyun Il
– fullname: SONG, Min Kyu
BookMark eNrjYmDJy89L5WQwCw12VfB3U_ALDQgyVPD0U3DxdHT38w_2DFZw9HNRCAlydQzxdfULAalxCnIEKggJ9fUP4mFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8eH-RgaGFgYGJkYmBo6GxsSpAgCKniok
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
Physics
DocumentTitleAlternate 뇌종양의 진단 및 치료에서의 NUPR1의 용도
UTILISATION DE NUPR1 DANS LE DIAGNOSTIC ET LE TRAITEMENT DE LA TUMEUR AU CERVEAU
ExternalDocumentID WO2018004240A1
GroupedDBID EVB
ID FETCH-epo_espacenet_WO2018004240A13
IEDL.DBID EVB
IngestDate Fri Aug 30 05:42:14 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
Korean
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_WO2018004240A13
Notes Application Number: WO2017KR06783
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180104&DB=EPODOC&CC=WO&NR=2018004240A1
ParticipantIDs epo_espacenet_WO2018004240A1
PublicationCentury 2000
PublicationDate 20180104
PublicationDateYYYYMMDD 2018-01-04
PublicationDate_xml – month: 01
  year: 2018
  text: 20180104
  day: 04
PublicationDecade 2010
PublicationYear 2018
RelatedCompanies SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
OPTIPHARM CO., LTD
RelatedCompanies_xml – name: OPTIPHARM CO., LTD
– name: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Score 3.104769
Snippet The present invention relates to use of nuclear protein 1 (NUPR1) in diagnosing and treating brain tumors and, more particularly, to a biomarker composition...
SourceID epo
SourceType Open Access Repository
SubjectTerms HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
TESTING
Title USE OF NUPR1 IN DIAGNOSIS AND TREATMENT OF BRAIN TUMOR
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180104&DB=EPODOC&locale=&CC=WO&NR=2018004240A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS8MwFD6MeX3TqXiZElD6VmxsensY0qubsHb0onsbbdaCKOuwFf--Sdx0T3sJJOcQTgInyXdyLgB3FqUWzh-wrFtUlYnKmhyTXCa6Sc3CKDVNlOkch_owI89TbdqBj3UsjMgT-i2SIzKNokzfW3FeL_-NWJ7wrWzuizc2VD8G6cCTVugYmxxeSJ4z8CeRF7mS6zLcJoXxL41_8yk2w0o7_CHNM-37Lw6PS1luXirBEexO2HyL9hg673UPDtx17bUe7I9XX9492BM-mrRhgys9bE5AzxIfRQEKs0mM0ShE3sh-CqNklCA79FAa-3bKs_RzHie2GUOajaP4FG4DP3WHMhNl9rfy2Wu0Kbd6Bt1FvSjPAWHNoLywpaVXCinzIqcKqYihYVUrK8OaX0B_20yX28lXcMi7wtJA-tBtP7_Ka3b3tsWN2LIfptGAdA
link.rule.ids 230,309,786,891,25594,76904
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8IwEL8Q_MA3RY0fqE00e1ukrtvYAzFjHzJlHRmb8rZsdSRGA0Rm_PdtKyhPvPTh7nJpm1wvv7b3O4AbizEL53dYNSymqUTjQ45JrhKjwzqFWeq6bNMZUqOfksexPq7Bx6oWRvKEfktyRB5RjMd7Jc_r-f8lliv_Vi5uizcumt37SddVlugYdwS8UNxe1xtGbuQojsNxm0LjX5145mvbHCttmRwUCqZ977kn6lLm60nF34ftIfc3rQ6g9j5rQsNZ9V5rwm64fPJuwo78o8kWXLiMw8UhGOnIQ5GPaDqMMQoocgP7gUajYIRs6qIk9uxEsPQLm15sc4MkDaP4CK59L3H6Kp9K9rfy7CVan7d2DPXpbFqeAMK6yURjS8uYtEmZFzlrkwkxdazp5cS0Xk-htcnT2Wb1FTT6STjIBgF9Ooc9oZK3DqQF9erzq7zgebgqLuX2_QDOvYNf
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=USE+OF+NUPR1+IN+DIAGNOSIS+AND+TREATMENT+OF+BRAIN+TUMOR&rft.inventor=KIM%2C+Yo+Na&rft.inventor=OH%2C+Mi+Kyoung&rft.inventor=PAEK%2C+Sun+Ha&rft.inventor=HAN%2C+Beom+Ku&rft.inventor=KIM%2C+Hyun+Il&rft.inventor=SONG%2C+Min+Kyu&rft.date=2018-01-04&rft.externalDBID=A1&rft.externalDocID=WO2018004240A1